SCHEMBL2659840

SCHEMBL2659840

CCN1Cc2nc3c(-c4cc(C)cc(C)c4)cccc3c(N)c2C1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRG2 P18507 2/20 0.43
▸ GABRB3 P28472 2/20 0.43
▸ GABRA2 P47869 2/20 0.43
▸ PDE5A O76074 3/20 0.35
▸ ENPP1 P22413 1/20 0.33
▸ BRD9 Q9H8M2 1/20 0.33
▸ BRD7 Q9NPI1 1/20 0.33
▸ CRHR1 P34998 3/20 0.33
▸ KMT2A Q03164 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ USP2 O75604 1/20 0.32
▸ ATM Q13315 1/20 0.32
▸ KEAP1 Q14145 1/20 0.32
▸ NFE2L2 Q16236 1/20 0.32
▸ CYP1B1 Q16678 1/20 0.32
▸ PIK3CD O00329 1/20 0.32
▸ PIK3CA P42336 1/20 0.32
▸ PIK3CG P48736 1/20 0.32
▸ LCK P06239 1/20 0.31
▸ BTK Q06187 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2656723 0.92 GABRG2 (0.44) GABRG2GABRB3GABRA2ENPP1BRD9
SCHEMBL2661141 0.87 PDE5A (0.40) GABRG2GABRB3GABRA2PDE5AENPP1
SCHEMBL2660620 0.86 GABRG2 (0.41) GABRG2GABRB3GABRA2ENPP1BRD9
SCHEMBL2661751 0.85 HSP90AA1 (0.37) GABRG2GABRB3GABRA2PDE5ALCK
SCHEMBL2660678 0.85 GABRG2 (0.45) GABRG2GABRB3GABRA2ENPP1CRHR1
SCHEMBL2661396 0.83 PDE5A (0.43) GABRG2GABRB3GABRA2PDE5ACRHR1
SCHEMBL2656333 0.83 PDE5A (0.44) PDE5AKMT2AMEN1PIK3CGKDM4E
SCHEMBL4921370 0.83 PDE5A (0.37) GABRG2GABRB3GABRA2PDE5AENPP1
SCHEMBL4922136 0.82 GABRG2 (0.48) GABRG2GABRB3GABRA2PDE5AGAA
SCHEMBL2660707 0.82 CRHR1 (0.41) GABRG2GABRB3GABRA2ENPP1CRHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP claimed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO claimed
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF GABRG2 592/4885GABRB3 332/4885GABRA2 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback